Allworth Financial LP Grows Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Allworth Financial LP lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 61.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,507 shares of the company’s stock after purchasing an additional 572 shares during the period. Allworth Financial LP’s holdings in IDEXX Laboratories were worth $649,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. Villere ST Denis J & Co. LLC lifted its position in shares of IDEXX Laboratories by 2.6% during the 4th quarter. Villere ST Denis J & Co. LLC now owns 62,442 shares of the company’s stock worth $25,816,000 after buying an additional 1,556 shares during the last quarter. Adell Harriman & Carpenter Inc. purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $413,000. V Square Quantitative Management LLC boosted its stake in IDEXX Laboratories by 6.2% during the 4th quarter. V Square Quantitative Management LLC now owns 2,076 shares of the company’s stock worth $858,000 after purchasing an additional 121 shares during the period. CFC Planning Co LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at $487,000. Finally, Vontobel Holding Ltd. boosted its stake in shares of IDEXX Laboratories by 90.1% during the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after buying an additional 198,404 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.4 %

NASDAQ IDXX opened at $452.89 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a 50-day moving average of $431.19 and a 200-day moving average of $452.42. The company has a market cap of $37.09 billion, a P/E ratio of 42.45, a P/E/G ratio of 3.38 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on IDXX shares. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.